GlassScriptPhysician profile
Parag Goyal
NPI 1528385556
$87,211.08
in general payments reported to CMS, 2019-2025
20 companies · $78K in 2025
The $78K reported for 2025 was more than what 96% of Advanced Heart Failure and Transplant Cardiology providers received nationally (typical 2025 total: $1,046).
See the full distribution for Advanced Heart Failure and Transplant Cardiology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $2,731 · 2021: $19.48 · 2022: $234 · 2023: $350 · 2024: $5,789 · 2025: $78K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $67K · Travel and Lodging: $8,518 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,464 · Food and Beverage: $2,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $67,077.00 |
| Travel and Lodging | $8,518.15 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,464.43 |
| Food and Beverage | $2,954.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $28,743.11 | 2025 | Amvuttra |
| Bayer Healthcare Pharmaceuticals INC. | $20,921.51 | 2024-2025 | |
| Pfizer INC. | $17,112.05 | 2024-2025 | |
| Bridgebio Pharma, INC. | $15,136.02 | 2025 | Attruby |
| Akcea Therapeutics, INC. | $2,669.80 | 2019-2020 | |
| Abbott Laboratories | $1,106.85 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Thoratec Heartmate 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $647.26 | 2025 | |
| Novartis Pharmaceuticals Corporation | $187.30 | 2019-2025 | |
| Biosense Webster, INC. | $148.15 | 2025 | Carto 3 |
| Abiomed | $135.77 | 2024 | Impella |
| Cvrx, INC. | $116.11 | 2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $109.13 | 2025 | |
| Edwards Lifesciences Corporation | $91.42 | 2025 | |
| Amgen INC. | $62.03 | 2020 | |
| Actelion Pharmaceuticals US, INC. | $24.57 | 2019 |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parag Goyal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.